MSK Library Guides: Precision Medicine: MeSH Search Tips

Medical Subject Headings (MeSH)

"Biomarkers"[Mesh]
Scope note: Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Year introduced: 2016(1989)
"Biomarkers, Tumor"[Mesh]
Scope note: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Year introduced: 2016(1988)
"Drug Screening Assays, Antitumor"[Mesh]
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Year introduced: 1988
"Epigenomics"[Mesh]
Scope note: The systematic study of the global gene expression changes due to EPIGENETIC PROCESSES and not due to DNA base sequence changes. Year introduced: 2011
"Gene Expression Regulation"[Mesh]
Scope note: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Year introduced: 1981
"Gene Expression Regulation, Neoplastic"[Mesh]
Scope note: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Year introduced: 1990
"Genes, Neoplasm"[Mesh]
Genes whose abnormal expression, or MUTATION are associated with the development, growth, or progression of NEOPLASMS. Year introduced: 2006
"Genetic Markers"[Mesh]
Scope note: A phenotypically recognizable genetic trait which can be used to identify a genetic locus, a linkage group, or a recombination event. Year introduced: 1989
"Genetic Phenomena"[Mesh]
Scope note: The processes, properties and biological objects that are involved in maintaining, expressing, and transmitting from one organism to another, genetically encoded traits. Year introduced: 2009
"Genetic Techniques"[Mesh]
Scope note: Chromosomal, biochemical, intracellular, and other methods used in the study of genetics. Year introduced: 1991
"Genetic Variation"[Mesh]
Scope note: Genotypic differences observed among individuals in a population. Year introduced: 2009 (1968)
"Genome, Human"[Mesh]
The complete genetic complement contained in the DNA of a set of CHROMOSOMES in a HUMAN. The length of the human genome is about 3 billion base pairs. Year introduced: 1990
"Genomics"[Mesh]
Scope note: The systematic study of the complete DNA sequences (GENOME) of organisms. Year introduced: 2001
"High-Throughput Nucleotide Sequencing"[Mesh]
Scope note: Techniques of nucleotide sequence analysis that increase the range, complexity, sensitivity, and accuracy of results by greatly increasing the scale of operations and thus the number of nucleotides, and the number of copies of each nucleotide sequenced. The sequencing may be done by analysis of the synthesis or ligation products, hybridization to preexisting sequences, etc. Year introduced: 2011
"Human Genome Project"[Mesh]
Scope note: A coordinated effort of researchers to map (CHROMOSOME MAPPING) and sequence (SEQUENCE ANALYSIS, DNA) the human GENOME. Year introduced: 1990
"Molecular Targeted Therapy"[Mesh]
Scope note: Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease. Year introduced: 2011
"Mutation"[Mesh]
Scope note: Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Year introduced: 1964
"Neoplasm Proteins"[Mesh]
Scope note: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
"Precision Medicine"[Mesh]
Scope note: Clinical, therapeutic and diagnostic approaches to optimal disease management based on individual variations in a patient's genetic profile. Year introduced: 2010
"Proteomics"[Mesh]
Scope note: The systematic study of the complete complement of proteins (PROTEOME) of organisms. Year introduced: 2003
"Sequence Analysis"[Mesh]
Scope note: A multistage process that includes the determination of a sequence (protein, carbohydrate, etc.), its fragmentation and analysis, and the interpretation of the resulting sequence information. Year introduced: 1993

Memorial Sloan Kettering Library

Precision Medicine: MeSH Search Tips

MeSH Tree

Use MeSH to Build a Better PubMed Query (3:02 min)

MeSH Tips

PubMed Search Tips

Medical Subject Headings (MeSH)